The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.

The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.

Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantially pure API of viloxazine HCl while avoiding undesirable impurities. The methods further provide for separating, identifying, and characterizing novel polymorphs of viloxazine. Further provided are methods for synthesis and identification and characterization of novel intermediates of viloxazine, as well as for some important metabolites and precursors of metabolites of viloxazine.

At least one of alertness, attention, focus and concentration may be enhanced in a person in need thereof, by a method including a step of administering a composition to the person, where the composition includes: a) between 20 mg and 5 g per dose of mangiferin, norathyriol, or an extract comprising mangiferin or norathyriol sufficient to provide between 20 mg and 5 g mangiferin or norathyriol per dose, wherein said extract comprising mangiferin or norathyriol is a mangiferin-containing extract of a plant species in a genus selected from the group consisting of Mangifera, Salacia, Cyclopia, Hypericum, Canscora, Fagraea, Gentiana, Hoppea, Swertia, Hypericum, Polygala, Zizyphus, and mixtures thereof; and b) caffeine.

At least one of alertness, attention, focus and concentration may be enhanced in a person in need thereof, by a method including a step of administering a composition to the person, where the composition includes: a) between 20 mg and 5 g per dose of mangiferin, norathyriol, or an extract comprising mangiferin or norathyriol sufficient to provide between 20 mg and 5 g mangiferin or norathyriol per dose, wherein said extract comprising mangiferin or norathyriol is a mangiferin-containing extract of a plant species in a genus selected from the group consisting of Mangifera, Salacia, Cyclopia, Hypericum, Canscora, Fagraea, Gentiana, Hoppea, Swertia, Hypericum, Polygala, Zizyphus, and mixtures thereof; and b) caffeine.

In one aspect, a composition of ginsenoside Rg3 and ginsenoside Rg5 and a preparation method thereof, as well as its application in manufacturing drugs, foods and health products for boosting immunity, enhancing anti-tumor effects, improving resistance to anti-tumor targeted drugs, mitigating toxic and side effects of radiotherapy and chemotherapy or improving anti-fatigue effects. The composition has advantages in rapid action, less toxicity and side effects and is suitable for long-term use. In another aspect, a safe, highly efficient and stable drug, food or health product which can be obtained by a simple preparation process suitable for industrial production and which can be easily scaled up. In yet another aspect, a new type of components and production process for manufacturing drugs, foods and health products for boosting immunity, enhancing anti-tumor effect, improving resistance to anti-tumor targeted drugs, mitigating toxic and side effects of radiotherapy and chemotherapy or improving anti-fatigue effect.

In one aspect, a composition of ginsenoside Rg3 and ginsenoside Rg5 and a preparation method thereof, as well as its application in manufacturing drugs, foods and health products for boosting immunity, enhancing anti-tumor effects, improving resistance to anti-tumor targeted drugs, mitigating toxic and side effects of radiotherapy and chemotherapy or improving anti-fatigue effects. The composition has advantages in rapid action, less toxicity and side effects and is suitable for long-term use. In another aspect, a safe, highly efficient and stable drug, food or health product which can be obtained by a simple preparation process suitable for industrial production and which can be easily scaled up. In yet another aspect, a new type of components and production process for manufacturing drugs, foods and health products for boosting immunity, enhancing anti-tumor effect, improving resistance to anti-tumor targeted drugs, mitigating toxic and side effects of radiotherapy and chemotherapy or improving anti-fatigue effect.

The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.

The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.

The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.